Plavix Pharmacogenomic Marker Highlighted In JAMA
This article was originally published in The Pink Sheet Daily
Executive Summary
Article and editorial discuss potential for testing for non-responders to Plavix to guide treatment. Issue will be central to Effient launch - but will cardiologists embrace genetic screening?
You may also be interested in...
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
Best of the IN VIVO Blog, August 2009
A selection of our favorite blog posts from August 2009 for stories not covered elsewhere in this month's IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).